Advances of Antimicrobial Peptide‐Based Biomaterials for the Treatment of Bacterial Infections

Li, Guoyu; Lai, Zhenheng; Shan, Anshan

doi:10.1002/advs.202206602

Cited by 60 publications

(43 citation statements)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cathelicidin has a short half-life in vivo, with some authors suggesting 1 h; 70 thus, LLKKK18 being a smaller peptide can also be rapidly degraded in body fluids, suffering proteolytic degradation and renal clearance. 28,71 This demonstrates that loading LLKKK18 in NPs efficiently protected the peptide from degradation and allowed us to observe slight glucoregulatory effects that, although not significantly different from the control, should be highlighted. It is likely that the release from the NPs was slow and sustained since the treatments were performed every other day.…”

Section: Acs Pharmacologymentioning

confidence: 99%

Targeting β Cells with Cathelicidin Nanomedicines Improves Insulin Function and Pancreas Regeneration in Type 1 Diabetic Rats

Cristelo,

Nunes,

Pinto

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is an incurable condition with an increasing incidence worldwide, in which the hallmark is the autoimmune destruction of pancreatic insulin-producing β cells. Cathelicidin-based peptides have been shown to improve β cell function and neogenesis and may thus be relevant while developing T1D therapeutics. In this work, a cathelicidin-derived peptide, LLKKK18, was loaded in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs), surface-functionalized with exenatide toward a GLP-1 receptor, aiming the β cell-targeted delivery of the peptide. The NPs present a mean size of around 100 nm and showed long-term stability, narrow size distribution, and negative ζ-potential (−10 mV). The LLKKK18 association efficiency and loading were 62 and 2.9%, respectively, presenting slow and sustained in vitro release under simulated physiologic fluids. Glucose-stimulated insulin release in the INS-1E cell line was observed in the presence of the peptide. In addition, NPs showed a strong association with β cells from isolated rat islets. After administration to diabetic rats, NPs induced a significant reduction of the hyperglycemic state, an improvement in the pancreatic insulin content, and glucose tolerance. Also remarkable, a considerable increase in the β cell mass in the pancreas was observed. Overall, this novel and versatile nanomedicine showed glucoregulatory ability and can pave the way for the development of a new generation of therapeutic approaches for T1D treatment.

show abstract

Section: Acs Pharmacologymentioning

confidence: 99%

Targeting β Cells with Cathelicidin Nanomedicines Improves Insulin Function and Pancreas Regeneration in Type 1 Diabetic Rats

Cristelo,

Nunes,

Pinto

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

show abstract

“…Due to the excellent biocompatibility, many AMPs such as plectasin, histatin, ghrelin, murepavadin, and hLF1-11 are in various stages of clinical trials and are promising to be approved as clinical therapeutic agents. 343…”

Section: Challenges For Nanoantibioticsmentioning

confidence: 99%

Recent advances in nanoantibiotics against multidrug-resistant bacteria

Li,

Liu,

Gong

et al. 2023

Nanoscale Adv.

View full text Add to dashboard Cite

show abstract

“…With the discovery and application of penicillin, human health and care present prosperous prospects in the field of fighting against microbes. However, bacteria continue to evolve and the abuse of anti-biotic leads to rapid and widespread drug resistance ( Roope et al, 2019 ; Li et al, 2023a ), which results in the increasingly difficult treatment of bacterial infections. Antibiotics administration against the bacterial infections can no longer catch up with the pace of bacterial evolution ( Chen et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Peroxidase-like MoS2/Ag nanosheets with synergistically enhanced NIR-responsive antibacterial activities

Zhao¹,

Cui²,

Cui³

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

Pathogenic microbial infections have been threatening public health all over the world, which makes it highly desirable to develop an antibiotics-free material for bacterial infection. In this paper, molybdenum disulfide (MoS2) nanosheets loaded with silver nanoparticles (Ag NPs) were constructed to inactive bacteria rapidly and efficiently in a short period under a near infrared (NIR) laser (660 nm) in the presence of H2O2. The designed material presented favorable features of peroxidase-like ability and photodynamic property, which endowed it with fascinating antimicrobial capacity. Compared with free MoS2 nanosheets, the MoS2/Ag nanosheets (denoted as MoS2/Ag NSs) exhibited better antibacterial performance against Staphylococcus aureus by the generated reactive oxygen species (ROS) from both peroxidase-like catalysis and photodynamic, and the antibacterial efficiency of MoS2/Ag NSs could be further improved by increasing the amount of Ag. Results from cell culture tests proved that MoS2/Ag3 nanosheets had a negligible impact on cell growth. This work provided new insight into a promising method for eliminating bacteria without using antibiotics, and could serve as a candidate strategy for efficient disinfection to treat other bacterial infections.

show abstract

Advances of Antimicrobial Peptide‐Based Biomaterials for the Treatment of Bacterial Infections

Cited by 60 publications

References 194 publications

Targeting β Cells with Cathelicidin Nanomedicines Improves Insulin Function and Pancreas Regeneration in Type 1 Diabetic Rats

Targeting β Cells with Cathelicidin Nanomedicines Improves Insulin Function and Pancreas Regeneration in Type 1 Diabetic Rats

Recent advances in nanoantibiotics against multidrug-resistant bacteria

Peroxidase-like MoS2/Ag nanosheets with synergistically enhanced NIR-responsive antibacterial activities

Contact Info

Product

Resources

About